A subset of available tumors (with matched blood) from patients enrolled in a phase I clinical trial testing a recombinant poliovirus, published by Desjardins et al. NEJM 2018 (<a href="https://pubmed.ncbi.nlm.nih.gov/29943666/">PMID:29943666</a>), were analyzed by whole exome sequencing and RNA-seq. It was discovered that low tumor mutation burden correlated with survival outcome, and also discovered that low tumor mutation burden correlated with higher inflammatory gene signatures by RNA-seq.

Very Low Tumor Mutation Burden Identifies Inflamed Recurrent    Glioblastomas Responsive to Cancer Immunotherapy

2 selected publications including "Recurrent Glioblastoma Treated with Recombinant Poliovirus" (658 citations)

Very Low Tumor Mutation Burden Identifies Inflamed Recurrent Glioblastomas Responsive to Cancer Immunotherapy

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy